title: Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy with lipid emulsion as a drug carrier in an animal model.
abstract: The purpose of this study was to investigate the potential pharmacokinetic advantage of pancreatic arterial infusion chemotherapy with lipid emulsion as a drug carrier for pancreatic cancer in a dog model. The 20% Intralipid, as a solvent, was used in the experimental animals with 2 ml/kg (group A) and 1 ml/kg (group B). Normal sodium as a solvent was used as a control with 2 ml/kg (group C) and 1 ml/kg (group D), respectively. Cisplatin (4 mg/kg) was infused into the proximal segment of the splenic artery. The concentrations of cisplatin were measured in plasma of the portal vein and in the liver and pancreas of groups A and C. The area under the concentration-time curve (AUC), the maximum plasma concentration (C(max)), and the elimination half-life (t(1/2)) in plasma were calculated and compared statistically. Compared with group C, the AUC and C(max) of group A were significantly lower (P<0.01 and P<0.01, respectively), the t 1/2 was longer (P<0.05), and the tissue cisplatin concentration of the pancreas was higher (P<0.05). Compared with group D, the AUC and C(max) of group B were significantly lower (P<0.01 and P<0.01, respectively) and the t(1/2) was longer (P<0.01). Pancreatic arterial infusion chemotherapy with lipid emulsion as a drug carrier can increase the local concentration and prolong the retention time of a drug.
authors.affiliation: Department of Radiology, PLA General Hospital, Beijing, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.forename: Mao-Qiang
authors.initials: MQ
authors.lastname: Wang
authors.forename: Feng
authors.initials: F
authors.lastname: Duan
authors.forename: Liu-Xin
authors.initials: LX
authors.lastname: Duan
authors.forename: Guo-Kun
authors.initials: GK
authors.lastname: Ao
authors.forename: Peng
authors.initials: P
authors.lastname: Song
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004285:Dogs; D004337:Drug Carriers / Q000008:administration & dosage / Q000493:pharmacokinetics; D004655:Emulsions / Q000008:administration & dosage / Q000493:pharmacokinetics; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007261:Infusions, Intra-Arterial / Q000379:methods*; D023421:Models, Animal; D010179:Pancreas / Q000098:blood supply; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010743:Phospholipids / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013024:Soybean Oil / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013157:Splenic Artery
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D004655:Emulsions; D005217:Fat Emulsions, Intravenous; D010743:Phospholipids; C545823:soybean oil, phospholipid emulsion; D013024:Soybean Oil; D002945:Cisplatin